Immuron Limited (IMRN) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) Comparison side by side

Immuron Limited (NASDAQ:IMRN) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immuron Limited 4 0.00 N/A -0.68 0.00
Eloxx Pharmaceuticals Inc. 10 0.00 N/A -1.47 0.00

Table 1 highlights Immuron Limited and Eloxx Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Immuron Limited and Eloxx Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Immuron Limited 0.00% 0% 0%
Eloxx Pharmaceuticals Inc. 0.00% -107.1% -88.5%

Institutional & Insider Ownership

Institutional investors owned 3.06% of Immuron Limited shares and 50.1% of Eloxx Pharmaceuticals Inc. shares. Insiders Competitively, owned 0.4% of Eloxx Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Immuron Limited 9.85% 23.53% -40.39% -53.76% -62.7% -38.45%
Eloxx Pharmaceuticals Inc. -0.12% -17.66% -28.55% -29.23% -46.1% -32.06%

For the past year Immuron Limited was more bearish than Eloxx Pharmaceuticals Inc.

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellersÂ’ diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.